HC Wainwright Has Pessimistic Outlook of KPTI Q2 Earnings

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) – Equities research analysts at HC Wainwright reduced their Q2 2026 earnings estimates for shares of Karyopharm Therapeutics in a research note issued to investors on Friday, July 31st. HC Wainwright analyst R. Burns now forecasts that the company will earn ($1.38) per share for the quarter, down from their previous forecast of ($0.81). HC Wainwright has a “Neutral” rating and a $3.00 price objective on the stock. The consensus estimate for Karyopharm Therapeutics’ current full-year earnings is ($3.24) per share. HC Wainwright also issued estimates for Karyopharm Therapeutics’ Q3 2026 earnings at ($1.05) EPS, Q4 2026 earnings at ($0.85) EPS and FY2026 earnings at ($4.10) EPS.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($1.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.45) by $0.21. The business had revenue of $35.07 million for the quarter, compared to the consensus estimate of $31.40 million.

A number of other equities research analysts have also weighed in on the stock. Piper Sandler lowered their price objective on shares of Karyopharm Therapeutics to $7.00 and set an “overweight” rating for the company in a report on Friday. Cantor Fitzgerald restated an “overweight” rating on shares of Karyopharm Therapeutics in a research report on Tuesday, June 9th. Robert W. Baird cut shares of Karyopharm Therapeutics from an “outperform” rating to a “neutral” rating and set a $3.00 target price on the stock. in a report on Friday. Royal Bank Of Canada reissued an “outperform” rating and set a $16.00 price target on shares of Karyopharm Therapeutics in a research report on Tuesday, July 21st. Finally, Weiss Ratings downgraded shares of Karyopharm Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $11.50.

Karyopharm Therapeutics Stock Performance

Karyopharm Therapeutics stock opened at $1.97 on Tuesday. Karyopharm Therapeutics has a fifty-two week low of $1.80 and a fifty-two week high of $10.99. The firm’s fifty day moving average price is $8.75 and its 200-day moving average price is $8.15. The stock has a market cap of $44.64 million, a P/E ratio of -0.13 and a beta of 0.90.

Hedge Funds Weigh In On Karyopharm Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Avidity Partners Management LP grew its holdings in shares of Karyopharm Therapeutics by 244.6% during the first quarter. Avidity Partners Management LP now owns 463,741 shares of the company’s stock valued at $2,583,000 after buying an additional 329,175 shares during the last quarter. Royal Bank of Canada lifted its stake in Karyopharm Therapeutics by 4.1% during the 1st quarter. Royal Bank of Canada now owns 60,399 shares of the company’s stock valued at $336,000 after acquiring an additional 2,399 shares during the period. Commodore Capital LP purchased a new stake in shares of Karyopharm Therapeutics during the 1st quarter valued at about $10,862,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Karyopharm Therapeutics in the first quarter worth approximately $108,000. Finally, Renaissance Technologies LLC raised its holdings in shares of Karyopharm Therapeutics by 75.9% during the first quarter. Renaissance Technologies LLC now owns 105,414 shares of the company’s stock valued at $587,000 after purchasing an additional 45,500 shares during the last quarter. Institutional investors own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.